A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 38/17 (2006.01) A61P 19/02 (2006.01) A61P 27/02 (2006.01) A61P 35/00 (2006.01) C12N 15/861 (2006.01) C12N 15/867 (2006.01) C12N 15/12 (2006.01) C12N 15/63 (2006.01)
Patent
CA 2434543
The present invention is directed to the inhibition of pathological angiogenesis in different tissues such as cancer, tumor, retinal or synovial tissue. It has been shown that over expression of RB2/p130 modulates the angiogenetic balance. It has been further shown that induction of RB2/p130 expression using a tetracyline-regulated gene expression system as well as viral-mediated gene delivery inhibits angiogenesis in vivo via pRb2/p130- mediated down-regulation of vascular endothelial growth factor (VEGF) protein expression in vivo.
La présente invention concerne l'inhibition d'une angiogenèse pathologique dans différents tissus, tels que ceux d'un cancer, d'une tumeur ou d'un tissu rétinal ou synovial. On a démontré qu'une surexpression de RB2/p130 module l'équilibre angiogénétique et que l'induction de l'expression de RB2/p130 à l'aide d'un système d'expression génique régulé par tétracyline, ainsi que la distribution génique à médiation virale inhibent l'angiogenèse in vivo par le biais d'une insensibilisation de la cellule à médiation pRb2/p130 de l'expression protéique du facteur de croissance vasculaire endothéliale (VEGF) in vivo.
Borden Ladner Gervais Llp
Sbarro Institute For Cancer Research And Molecular Medicine
LandOfFree
Inhibition of pathological angiogenesis in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of pathological angiogenesis in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of pathological angiogenesis in vivo will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1372636